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Abstract
Oxidation is a fundamental process in chemistry and biology.  In synthetic
chemistry, there are several methods for the asymmetric oxidation of organic substrates.
Classically, these methods have focused on the delivery of a heteroatom from a reagent
or catalyst to a prochiral substrate.  What have historically been underdeveloped are
enantioselective oxidation methods that do not involve the transfer of a heteroatom,
butrather are defined by the enantioselective dehydrogenation of an organic substrate.
This type of oxidative transformation was investigated using a palladium(II) catalyst
system.
A palladium-catalyzed oxidative kinetic resolution of secondary alcohols was
developed.  Key features of the catalytic system include the use of (–)-sparteine as the
source of chiral relay, and molecular oxygen as the sole stoicheometric oxidant.  Under
the described catalytic system, a number of benzylic and allylic alcohols have been
oxidized in an enantioselective manner, to provide a ketone and residual alcohol in high
enantiomeric excess and excellent yield.
Subsequent to the original system, the systematic investigation of a number of
mechanistic hypotheses involving the role of exogenous bases and H-bonding additives
prompted the discovery of new reaction conditions displaying greatly enhanced
reactivity, selectivity, atom economy, and generality.  The net result of these
improvements was a catalytic system effective in oxidative desymmetrization of a
number of complex meso-diols.  Ultimately, these advances have permitted our method to
be applied towards a number of synthetic endeavors, including the key step in the total
synthesis of the natural product alkaloid (–)-lobeline.
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Boc tert-butyloxycarbonyl
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